A Study of a Single Dose of ALXN1210 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 27, 2014

Primary Completion Date

March 13, 2015

Study Completion Date

March 13, 2015

Conditions
Healthy
Interventions
DRUG

ALXN1210

All doses of ALXN1210 were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 milliliters \[mL\]/hour), excluding interruption for safety or technical reason.

DRUG

Placebo

All doses of placebo were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 mL/hour), excluding interruption for safety or technical reason.

Trial Locations (1)

Unknown

Clinical Trial Site, Montreal

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY